.png "back to home page")
Despite targeting insoluble ABeta aggregates and early stage AD patients, 2 phase III clincial trials halted. Implications for targeting Abeta (even with early stage AD)..Need to restore synapse functions in MCI, slow down cell death in AD https://t.co/Tmb5uSZ675
— Amar Sahay (@AmarSahay_) March 21, 2019
Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment https://t.co/cpXYx52CeM via @statnews
— The Dana Foundation? (@dana_fdn) March 21, 2019
BREAKING: Biogen halts study of closely watched Alzheimer’s drug, a blow to hopes for new treatment https://t.co/TbsYAz96PI
— STAT (@statnews) March 21, 2019
No no no . . . even those who have been questioning the #amyloid hypothesis in #Alzheimers (and lamenting its hegemony) have gotta greet this news with immense sadness. https://t.co/hz5BxBWCYA ? $BIIB
— sharon begley (@sxbegle) March 21, 2019
This is a very big deal, and very sad. https://t.co/WxN8rezGYv
— Jason Ukman (@JasonUkman) March 21, 2019
Another amyloid-based drug trial fails. When is enough enough?? Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment https://t.co/CGeZrAn11r via @statnews
— Tia Powell (@tiapowell) March 21, 2019
Biogen halts study of closely watched Alzheimer’s drug, a blow to hopes for new treatment https://t.co/ZA7wnzVMLm $BIIB
— Adam Feuerstein (@adamfeuerstein) March 21, 2019
This would not have been a shock to anyone who follows @TuitNutrition - seems investors lost out big, too. Thanks, Amy for enlightening any who listen!
— Sandra Carusetta (@SCarusetta) March 21, 2019
Biogen halts study of Alzheimer’s drug, a blow to hopes for new treatment https://t.co/kkSTrx9osw
Biogen and Eisai now join a long list of drug companies that have tried but failed to develop successful treatments for Alzheimer’s.#Biogen #Alzheimers #Dementia @statnews https://t.co/wZs9SU9MMs
— Nicole Saphier, MD (@NBSaphierMD) March 21, 2019
The move has put the stock on track for its biggest one-day percentage slide since August of 2008. https://t.co/COrqfMvjxS
— Sarah Toy (@sarahtoy17) March 21, 2019
Another stopped study, now Biogen, after Pfizer, and a lot of other major pharmaceutical companies ... #healthcare #medicine #ai #research https://t.co/tdXTHCmD0W
— Armin Furtwaengler (@0c959fa2c845485) March 21, 2019
Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment https://t.co/GWiR326bBb via @statnews
— Carl Zimmer (@carlzimmer) March 22, 2019
Scientists stop studies of #Alzheimer drug aducanumab, another blow to hopes for new treatment - @statnews @adamfeuerstein https://t.co/O9Ws9MZhXW
— Avis Favaro (@CTV_AvisFavaro) March 21, 2019
Very sad. There was so much hope about this trial. https://t.co/9cY5yn0qNL via @statnews
— Victor H Bustos (@VHugoBustos) March 21, 2019
Biogen halts study of Alzheimer’s drug, a blow to hopes for new treatment - We must push other strategies! https://t.co/fhg1YrLQxf
— IdoAmitLab (@IdoAmitLab) March 21, 2019
https://t.co/DJs909IZiL
— Hofmann-Apitius (@ApitiusHofmann) March 21, 2019
This is a major blow to all people who still target the amyloid cascade. I wonder, how pharma industry and funding bodies will respond to this last failure of an amyloid - targeting approach.
btw: no reason to be cheerful. This is sad news.
https://t.co/mDU2hubVvz Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment 2상 임상을 넘지 못하다니... 알츠하이머 정복은 이렇게 힘들다.
— Park JaeHo (@jrogue) March 22, 2019
Biogen halts study of Alzheimer’s drug, a blow to hopes for new treatment. Unfortunate outcome... https://t.co/wAtPbSJv0D
— Omid Veiseh (@veiseho) March 21, 2019
Biogen・ EisaiがAD薬 #aducanumab のP3を放棄。Biogen株は26%ダウン。https://t.co/Q4KitTMdO7
— silex知の文献サービス (@silex_transl) March 21, 2019
Did you see this? The same thing that happened with the Lilly study that Sue was on. https://t.co/iPq2fYXgmT
— BeantownDoug-ish (@Beantowndougish) March 21, 2019